



Post Authorisation Assessments

Vanguard Lepto ci Vm 42058/5181

09 January 2026	To add an already authorised site for Physical/Chemical testing of the finished product to the manufacturing flow chart.
14 January 2025	Change in legal entity of MA holder for Northern Ireland only from Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP to Zoetis Belgium S.A., 2nd Floor, Building 10, Cherrywood Business Park, Loughlinstown, Dublin 18, D18 T3Y1 Ireland.
18 November 2022	Introduction of in vitro antigen capture ELISA potency test. Use of antigen capture ELISA to quantify antigen.
22 October 2019	Change in the address of the marketing authorisation holder from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Zoetis UK Limited, 1st Floor, Birchwood Building, Springfield Drive, Leatherhead, Surrey, KT22 7LP.
13 November 2018	Change in the contact details of the QPPV of an existing pharmacovigilance system as described in the DDPS.
05 May 2015	Change in the QPPV contact details.
10 October 2013	Change to the name of the active substance manufacturer. Change to the name of the manufacturer responsible for the finished product and batch release. Change in the QPPV contact details.
31 July 2013	Change of MAH and Distributor to: Zoetis UK Ltd.
10 February 2012	Variation to allow the simultaneous administration of Vanguard Lepto ci and Vanguard R, either within the same syringe or at different injection sites.
18 November 2010	Removal of target animal batch safety test
03 March 2010	Mutual Recognition procedure
17 February 2010	Additions of suppliers of materials of animal origin sourced from BSE-free countries.